NCT06181656Recruiting
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
Source: ClinicalTrials.gov · Last updated 20 May 2026
Brief summary (registry, in English)
To learn how radiation treatment may affect your responses to vaccines against pneumonia.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 13 Dec 2023
- Start date
- 5 Feb 2024
- Primary completion date
- 4 Jul 2027
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06181656
What you commit to
- Study type: Observational
- Planned participants: 80
- From 5 Feb 2024 to the primary completion date, 4 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., Human immunodeficiency virus (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
- Patients receiving intravenous immunoglobulin (IVIG) during the study or in the three months prior to study enrollment.
- Individuals with previous pneumococcal vaccination in the last 5 years.
Other illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements.
- Individuals with severe allergy to any of the vaccine components
Who the study is looking for
- Group 1A
- Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with protons.
- Group 1B
- Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with intensity-modulated radiation therapy (IMRT)
- Group 2A
- Patients currently receiving, planning to receive, or recently completed definitive proton therapy for unresectable liver cancer.
- Group 2B
- Patients currently receiving, planning to receive, or recently completed definitive IMRT for unresectable liver cancer.
- Group 3
- Healthy age- and gender- matched individuals
- All Groups
- Patients of all genders, races and nationalities will be solicited.
- Age \>18 years
- Ability to understand and the willingness to sign a written informed consent document.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.